路透7月7日 - 凯莱拉制药公司(KLRA.O)周二表示,其用于治疗糖尿病和肥胖症患者的GLP-1药物在两项后期临床试验中达到了主要目标。
路透7月7日 - 凯莱拉制药公司(KLRA.O)周二表示,其用于治疗糖尿病和肥胖症患者的GLP-1药物在两项后期临床试验中达到了主要目标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.